Vicapsys Life Sciences, Inc. (VICP)
Oxford Ledge is still expanding full research coverage of VICP. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Vicapsys develops encapsulated therapeutic product candidates using CXCL12 technology for transplantation and anti-fibrosis applications under license from Massachusetts General Hospital.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2025-01-10
- 10-Q Quarterly financial report (unaudited) 2025-01-10
- 10-Q Quarterly financial report (unaudited) 2025-01-10
- 10-K Annual financial report with audited statements 2024-10-21
- 8-K Entry into material agreement; Creation of direct financial obligation; Financial statements and exhibits 2023-12-27
Source: SEC EDGAR.
- Open VICP in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.